Treatment of B-Cell Lymphoma

  • Michael Voulgarelis
  • Haralampos M. Moutsopoulos


Sjögren’s syndrome (SS) displays the highest incidence of malignant lymphoproliferative disorders among all of the autoimmune diseases. This association was highlighted in studies performed at the National Institutes of Health in the 1970s [1, 2] and verified in a meta-analysis that estimated the risk of Non-Hodgkin’s lymphoma (NHL) among the classic autoimmune diseases [3]. This meta-analysis reported that the possibility of an overt malignant lymphoproliferation is higher among SS patients (random effects standardized incidence rate (SIR) of 18.9 [95% confidence interval 9.4, 37.9]).


Marginal Zone International Prognostic Index Marginal Zone Lymphoma Extranodal Site Lymphoepithelial Lesion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Kassan SS, Thomas TL, Moutsopoulos HM, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med. 1978;89:888-92.PubMedGoogle Scholar
  2. 2.
    Bunim JJ, Talal N. Development of malignant lymphoma in the course of Sjogren’s syndrome. Trans Assoc Am Physicians. 1963;76:45-56.Google Scholar
  3. 3.
    Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med. 2005;165:2337-44.PubMedCrossRefGoogle Scholar
  4. 4.
    Suarez F, Lortholary O, Hermine O, et al. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood. 2006;107:3034-44.PubMedCrossRefGoogle Scholar
  5. 5.
    Voulgarelis M, Dafni UG, Isenberg DA, et al. Malignant lymphoma in primary Sjogren’s syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren’s Syndrome. Arthritis Rheum. 1999;42:1765-72.PubMedCrossRefGoogle Scholar
  6. 6.
    Baimpa E, Dahabreh IJ, Voulgarelis M, et al. Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore). 2009;88:284-93.CrossRefGoogle Scholar
  7. 7.
    Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol. 2000;13:193-207.PubMedCrossRefGoogle Scholar
  8. 8.
    Royer B, Cazals-Hatem D, Sibilia J, et al. Lymphomas in patients with Sjogren’s syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites and are not associated with viruses. Blood. 1997;90:766-75.PubMedGoogle Scholar
  9. 9.
    Smedby KE, Hjalgrim H, Askling J, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst. 2006;98:51-60.PubMedCrossRefGoogle Scholar
  10. 10.
    Theander E, Henriksson G, Ljungberg O, et al. Lymphoma and other malignancies in primary Sjogren’s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis. 2006;65:796-803.PubMedCrossRefGoogle Scholar
  11. 11.
    Pelstring RJ, Essell JH, Kurtin PJ, Cohen AR, Banks PM. Diversity of organ site involvement among malignant lymphomas of mucosa-associated tissues. Am J Clin Pathol. 1991;96:738-45.PubMedGoogle Scholar
  12. 12.
    Dogan A, Du M, Koulis A, et al. Expression of lymphocyte homing receptors and vascular addressins in low-grade gastric B-cell lymphomas of mucosa-associated lymphoid tissue. Am J Pathol. 1997;151:1361-9.PubMedGoogle Scholar
  13. 13.
    Bahler DW, Swerdlow SH. Clonal salivary gland infiltrates associated with myoepithelial sialadenitis (Sjogren’s syndrome) begin as nonmalignant antigen-selected expansions. Blood. 1998;91:1864-72.PubMedGoogle Scholar
  14. 14.
    Martin T, Weber JC, Levallois H, et al. Salivary gland lymphomas in patients with Sjogren’s syndrome may frequently develop from rheumatoid factors B cells. Arthritis Rheum. 2000;43:908-16.PubMedCrossRefGoogle Scholar
  15. 15.
    D’Elios MM, Manghetti M, Almerigogna F, et al. Different cytokine profile and antigen-specificity repertoire in Helicobacter pylori-specific T cell clones from the antrum of chronic gastritis patients with or without peptic ulcer. Eur J Immunol. 1997;27:1751-5.PubMedCrossRefGoogle Scholar
  16. 16.
    Isaacson PG, Spencer J. Malignant lymphoma of mucosa-associated lymphoid tissue. Histopathology. 1987;11:445-62.PubMedCrossRefGoogle Scholar
  17. 17.
    DiGiuseppe JA, Corio RL, Westa WH. Lymphoid infiltrates of the salivary glands: pathology, biology and clinical significance. Curr Opin Oncol. 1996;8:232-7.PubMedCrossRefGoogle Scholar
  18. 18.
    Stott DI, Hiepe F, Hummel M, et al. Antigen-driven clonal proliferation of B cells within target tissue of an autoimmune disease. The salivary glands of patients with Sjogren’s syndrome. J Clin Invest. 1998;102:938-46.PubMedCrossRefGoogle Scholar
  19. 19.
    Adamson TC, Fox RI, Frisman DM, et al. Immunohistologic analysis of lymphoid infiltrates in primary Sjogren’s syndrome using monoclonal antibodies. J Immunol. 1983;130:203-8.PubMedGoogle Scholar
  20. 20.
    Boumba D, Skopouli FN, Moutsopoulos HM. Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sjogren’s syndrome. Br J Rheumatol. 1995;34:326-33.PubMedCrossRefGoogle Scholar
  21. 21.
    Zinzani PL, Magagnoli M, Galieni P, et al. Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. J Clin Oncol. 1999;17:1254-8.PubMedGoogle Scholar
  22. 22.
    Zucca E, Conconi A, Pedrinis E, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood. 2003;101:2489-95.PubMedCrossRefGoogle Scholar
  23. 23.
    Thieblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood. 2000;95:802-6.PubMedGoogle Scholar
  24. 24.
    Ambrosetti A, Zanotti R, Pattaro C, et al. Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection. Br J Haematol. 2004;126:43-9.PubMedCrossRefGoogle Scholar
  25. 25.
    Montalbán C, Castrillo JM, Abraira V, et al. Gastric B-cell mucosa-associated lymphoid tissue (MALT) lymphoma. Clinicopathological study and evaluation of the prognostic factors in 143 patients. Ann Oncol. 1995;6:355-62.PubMedGoogle Scholar
  26. 26.
    Thieblemont C, Bastion Y, Berger F, et al. Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. J Clin Oncol. 1997;15:1624-30.PubMedGoogle Scholar
  27. 27.
    Radaszkiewicz T, Dragosics B, Bauer P. Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue: factors relevant to prognosis. Gastroenterology. 1992;102:1628-38.PubMedGoogle Scholar
  28. 28.
    Hammel P, Haioun C, Chaumette MT, et al. Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol. 1995;13:2524-9.PubMedGoogle Scholar
  29. 29.
    Conconi A, Martinelli G, Thiéblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003;102:2741-5.PubMedCrossRefGoogle Scholar
  30. 30.
    Jäger G, Neumeister P, Brezinschek R, et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol. 2002;20:3872-7.PubMedCrossRefGoogle Scholar
  31. 31.
    Voulgarelis M, Petroutsos G, Moutsopoulos HM, et al. 2-chloro-2-deoxyadenosine in the treatment of Sjogren’s syndrome-associated B cell lymphoproliferation. Arthritis Rheum. 2002;46:2248-9.PubMedCrossRefGoogle Scholar
  32. 32.
    Hussell T, Isaacson PG, Crabtree JE, et al. Helicobacter pylori-specific tumour-infiltrating T cells provide contact dependent help for the growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue. J Pathol. 1996;178:122-7.PubMedCrossRefGoogle Scholar
  33. 33.
    Pijpe J, van Imhoff GW, Vissink A, et al. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren’s syndrome and associated MALT lymphoma. Ann Rheum Dis. 2005;64:958-60.PubMedCrossRefGoogle Scholar
  34. 34.
    Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjogren’s syndrome: an open-label phase II study. Arthritis Rheum. 2005;52:2740-50.PubMedCrossRefGoogle Scholar
  35. 35.
    Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren’s syndrome. Ann Rheum Dis. 2007;66:351-7.PubMedCrossRefGoogle Scholar
  36. 36.
    Quartuccio L, Fabris M, Moretti M, et al. Resistance to rituximab therapy and local BAFF overexpression in Sjögren’s syndrome-related myoepithelial sialadenitis and low-grade parotid B-cell lymphoma. Open Rheumatol J. 2008;2:38-43.PubMedCrossRefGoogle Scholar
  37. 37.
    De Vita S, Dolcetti R, Ferraccioli G, et al. Local cytokine expression in the progression toward B cell malignancy in Sjögren’s syndrome. J Rheumatol. 1995;22:1674-80.PubMedGoogle Scholar
  38. 38.
    Gong Q, Ou Q, Ye S, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol. 2005;174:817-26.PubMedGoogle Scholar
  39. 39.
    Hainsworth JD, Litchy S, Burris HA 3rd, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:4261-7.PubMedCrossRefGoogle Scholar
  40. 40.
    Salar A, Domingo-Domenech E, Estany C, et al. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Cancer. 2009;115:5210-7.PubMedCrossRefGoogle Scholar
  41. 41.
    Orciuolo E, Buda G, Sordi E, et al. 2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma. Leuk Res. 2010;34:184-9.PubMedCrossRefGoogle Scholar
  42. 42.
    Streubel B, Huber D, Wohrer S, et al. Frequency of chromosomal aberrations involving MALT1 in mucosa-associated lymphoid tissue lymphoma in patients with Sjogren’s syndrome. Clin Cancer Res. 2004;10:476-80.PubMedCrossRefGoogle Scholar
  43. 43.
    Lévy M, Copie-Bergman C, Gameiro C, et al. Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy. J Clin Oncol. 2005;23:5061-6.PubMedCrossRefGoogle Scholar
  44. 44.
    Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet. 2001;357(9249):39-40.PubMedCrossRefGoogle Scholar
  45. 45.
    Martinelli G, Laszlo D, Ferreri AJ, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin’s lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol. 2005;23:1979-83.PubMedCrossRefGoogle Scholar
  46. 46.
    Berger F, Felman P, Thieblemont C, et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood. 2000;95:1950-6.PubMedGoogle Scholar
  47. 47.
    Nathwani BN, Anderson JR, Armitage JO, et al. Marginal zone B-cell lymphoma: a clinical comparison of nodal and mucosa-associated lymphoid tissue types Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol. 1999;17:2486-92.PubMedGoogle Scholar
  48. 48.
    Shin SS, Sheibani K. Monocytoid B-cell lymphoma. Am J Clin Pathol. 1993;99:421-5.PubMedGoogle Scholar
  49. 49.
    Koh LP, Lim LC, Thng CH. Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma. Med Oncol. 2000;17:225-8.PubMedCrossRefGoogle Scholar
  50. 50.
    Voulgarelis M, Giannouli S, Anagnostou D, et al. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjogren’s syndrome-associated B-cell aggressive non-Hodgkin’s lymphomas. Rheumatology (Oxford). 2004;43:1050-3.CrossRefGoogle Scholar
  51. 51.
    Voulgarelis M, Giannouli S, Tzioufas AG, et al. Long-term remission of Sjögren’s syndrome-associated aggressive B-cell non-Hodgkin’s lymphomas following administration of combined B-cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann Rheum Dis. 2006;65:1033-7.PubMedCrossRefGoogle Scholar
  52. 52.
    Brown JR, Gaudet G, Friedberg JW, et al. Autologous bone marrow transplantation for marginal zone non-Hodgkin’s lymphoma. Leuk Lymphoma. 2004;45:315-20.PubMedCrossRefGoogle Scholar
  53. 53.
    Rossi D, Gaidano G. Molecular heterogeneity of diffuse large B-cell lymphoma: implications for disease management and prognosis. Hematology. 2002;7:239-52.PubMedCrossRefGoogle Scholar
  54. 54.
    Neumeister P, Hoefler G, Beham-Schmid C, et al. Deletion analysis of the p16 tumor suppressor gene in gastrointestinal mucosa-associated lymphoid tissue lymphomas. Gastroenterology. 1997;112:1871-5.PubMedCrossRefGoogle Scholar
  55. 55.
    Pui CH, Thiel E. Central nervous system disease in hematologic malignancies: historical perspective and practical applications. Semin Oncol. 2009;36(4 Suppl 2):S2-16.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2011

Authors and Affiliations

  • Michael Voulgarelis
    • 1
  • Haralampos M. Moutsopoulos
    • 1
  1. 1.Department of Pathophysiology, School of MedicineNational University of AthensAthensGreece

Personalised recommendations